These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35793222)

  • 1. A randomized Bayesian optimal phase II design with binary endpoint.
    Ding Y
    J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal futility stopping boundaries for binary endpoints.
    Freitag MM; Li X; Rauch G
    BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian Sequential Monitoring of Single-Arm Trials: A Comparison of Futility Rules Based on Binary Data.
    Sambucini V
    Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian optimal phase II clinical trial design with time-to-event endpoint.
    Zhou H; Chen C; Sun L; Yuan Y
    Pharm Stat; 2020 Nov; 19(6):776-786. PubMed ID: 32524679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian sequential design with binary outcome.
    Zhu H; Yu Q; Mercante DE
    Pharm Stat; 2017 May; 16(3):192-200. PubMed ID: 28251815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
    Guo B; Liu S
    Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
    Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
    Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Bayesian early stopping boundaries for phase II clinical trials.
    Jiang L; Yan F; Thall PF; Huang X
    Pharm Stat; 2020 Nov; 19(6):928-939. PubMed ID: 32720462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.
    Lin R; Coleman RL; Yuan Y
    J Natl Cancer Inst; 2020 Jan; 112(1):38-45. PubMed ID: 30924863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian two-stage design for phase II oncology trials with binary endpoint.
    Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
    Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
    Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
    Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A confidence function-based posterior probability design for phase II cancer trials.
    Shan M
    Pharm Stat; 2021 May; 20(3):485-498. PubMed ID: 33336856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal timing for an accelerated interim futility analysis incorporating real world data.
    Haine LMF; Murray TA; Koopmeiners JS
    Contemp Clin Trials; 2024 May; 140():107489. PubMed ID: 38461938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.